Quinoline-and isoquinoline-sulfonamide analogs of aripiprazole: Novel antipsychotic agents?

Future Medicinal Chemistry

Volumn 6, Issue 1, 2014, Pages 57-75

  Zajdel, Pawel ^a   Partyka, Anna ^a   Marciniec, Krzysztof ^b   Bojarski, Andrzej J ^c   Pawlowski, MacIej ^a   Wesolowska, Anna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BREXPIPRAZOLE; CARIPRAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ISOQUINOLINE DERIVATIVE; NEUROLEPTIC AGENT; QUINOLINE DERIVATIVE; SULFONAMIDE;

BEHAVIOR; CLINICAL EVALUATION; DRUG RECEPTOR BINDING; FUNCTIONAL ASSESSMENT; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; ISOQUINOLINES; PIPERAZINES; PROTEIN BINDING; QUINOLINES; QUINOLONES; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SULFONAMIDES;

EID: 84891290033     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.158     Document Type: Review

References (106)

1. Freedman R. Schizophrenia. N. Engl. J. Med. 349(18), 1738-1749 (2003).
2. Insel TR. Rethinking schizophrenia. Nature 468(7321), 187-193 (2010).
3. Van Os J, Kapur S. Schizophrenia. Lancet 374(9690), 635-645 (2009).
4. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153(4), 466-476 (1996).
5. Juckel G, Schlagenhauf F, Koslowski M et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29(2), 409-416 (2006).
6. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160(1), 13-23 (2003).
7. Buckley PF, Miller BJ, Lehrer DS et al. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 35(2), 383-402 (2009).
8. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 56(25), 2209-2222 (1995).
9. Herbert Y, Meltzer MD. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21, 106S-115S (1999).
10. Kleven MS, Barret-Grévoz C, Bruins Slot L et al. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49(2), 135-143 (2005).
11. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 10(4), 317-336 (2004).
12. Morozova MA, Lepilkina TA, Rupchev GE et al. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectr. 17, 1-8 (2013).
13. Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol. Biochem. Behav. 99(2), 245-253 (2011).
14. Miyamoto S, Miyake N, Jarskog LF et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17(12), 1206-1227 (2012).
15. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin. Emerg. Drugs 13(3), 479-495 (2008).
16. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl.) 99(Suppl.), S18-S27 (1989).
17. Butini S, Gemma S, Campiani G et al. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J. Med. Chem. 52(1), 151-169 (2009).
18. Leung JY, Barr AM, Procyshyn RM et al. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol. Ther. 135(2), 113-122 (2012).
19. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3(4), 353-359 (2004).
20. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11(1), 59-67 2011.
21. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr. Pharm. Des. 16(5), 488-501 (2010).
22. Juruena MF, De Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc. Patient Saf. 2, 205-211 (2010).
23. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 18(13), 933-956 (2004).
24. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl). 124(1-2), 2-34 (1996).
25. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl). 148(1), 3-15 (2000).
26. Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41 (2009).
27. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896), 951-962 (2013).
28. Lencz T, MalhotraAK. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin.Neurosci. 11(4), 405-415 (2009).
29. Marder SR. Overview of partial compliance. J. Clin. Psychiatry 64(Suppl. 16), 3-9 (2003).
30. Agid Y, Buzsáki G, Diamond DM et al. How can drug discovery for psychiatric disorders be improved? Nat. Rev. Drug Discov. 6(3), 189-201 (2007).
31. Buchanan RW, Davis M, Goff D et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31(1), 5-19 (2005).
32. Harvey PD. Current status of the MATRICS/TURNS initiative. Psychiatry (Edgmont) 3(10), 24-33 (2006).
33. Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 12(10), 904-922 (2007).
34. Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 291(1), 161-170 (1999).
35. Schlumberger C, Schäfer D, Barberi C et al. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav. Pharmacol. 20(1), 56-66 (2009).
36. Pehrson AL, Moghaddam B. Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion. Psychopharmacology (Berl.) 211(4), 443-455 (2010).
37. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281(5381), 1349-1352 (1998).
38. Hackler EA, Byun NE, Jones CK et al. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience 168(1), 209-218 (2010).
39. Galici R, Echemendia NG, Rodriguez AL, Conn PJ. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthostericm Glu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315, 1181-1187 (2005).
40. Liu F, Grauer S, Kelley C, Navarra R et al. ADX47273 [S-(4-fluoro-phenyl) -{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J. Pharmacol. Exp. Ther. 327(3), 827-839 (2008).
41. Kinney GG, O'Brien JA, Lemaire W et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 313, 199-206 (2005).
42. Spear N, Gadient RA, Wilkins DE et al. Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. Eur. J. Pharmacol. 659(2-3), 146-154 (2011).
43. Kinney GG, Sur C, Burno M et al. The glycine transporter type 1 inhibitor N-[3-(4́-fluorophenyl)-3-(4́-phenylphenoxy) propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. 23(20), 7586-7591 (2003).
44. Black MD, Varty GB, Arad M et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl.) 202(1-3), 385-396 (2009).
45. Boulay D, Bergis O, Avenet P, Griebel G. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 35(2), 416-427 (2010).
46. Jones CK, Brady AE, Davis AA et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 28(41), 10422-10433 (2008).
47. Bradley SR, Lameh J, Ohrmund L et al. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58(2), 365-373 (2009).
48. Ma L, Seager MA, Wittmann M et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc. Natl Acad. Sci. USA 106, 15950-15955 (2009).
49. Chambon C, Wegener N, Gravius A, Danysz W. A new automated method to assess the rat recognition memory: validation of the method. Behav. Brain Res. 222, 151-157 (2011).
50. Brady AE, Jones CK, Bridges TM et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther. 327(3), 941-953 (2008).
51. Hauser TA, Kucinski A, Jordan KG et al. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol. 78(7), 803-812 (2009).
52. Young JW, Meves JM, Geyer MA. Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav. Brain Res. 240, 119-133 (2013).
53. Halene TB, Siegel SJ. Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle. J. Pharmacol. Exp. Ther. 326(1), 230-239 (2008).
54. Yang SW, Smotryski J, McElroy WT et al. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. Bioorg. Med. Chem. Lett. 22(1), 235-239 (2012).
55. Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin. Neurosci. 8(1), 109-113 (2006).
56. Buchanan RW, Freedman R, Javitt DC et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull. 33(5), 1120-1130 (2007).
57. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3(4), 353-359 (2004).
58. De Oliveira IR, Elkis H, Gattaz WF et al. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. CNS Spectr. 14(2), 93-102 (2009).
59. Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J. Med. Invest. 52(Suppl.), 284-290 (2005).
60. Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61, 123-136 (2003).
61. McQuade RD, Stock E, Marcus R et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 65(Suppl. 18), 47-56 (2004).
62. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidonevs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60(7), 681-690 (2003).
63. Lawler CP, Prioleau C, Lewis MM et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 20(6), 612-627 (1999).
64. Hirose T, Uwahodo Y, Yamada S et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J. Psychopharmacol. 18(3), 375-383 (2004).
65. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302(1), 381-389 (2002).
66. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr. Drug Targets CNS Neurol. Disord. 1(2), 141-147 (2002).
67. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18(4), 251-267 (2004).
68. Burda K, Czubak A, Kus K et al. Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol. Rep. 63(4), 898-907 (2011).
69. Blier P, Blondeau C. Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J. Affect.Disord. 128(Suppl. 1), S3-S10 (2011).
70. Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8), 1400-1411 (2003).
71. Urban JD, Clarke WP, von Zastrow M et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320(1), 1-13 (2007).
72. Kenakin T. Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336(2), 296-302 (2011).
73. Nordquist RE, Risterucci C, Moreau JL et al. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 54(2), 405-416 (2008).
74. Fejgin K, Safonov S, Pålsson E et al. The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology 191(2), 377-385 (2007).
75. Bruins Slot LA, Kleven MS, Newman-Tancredi. A Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49(7), 996-1006 (2005).
76. Nagai T, Murai R, Matsui K et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl.) 202(1-3), 315-328 (2009).
77. Kiss B, Horvath A, Nemethy Z et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 333, 328-340 (2010).
78. Gyertyán I, Kiss B, Sághy K et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem. Int. 59(6), 925-935 (2011).
79. Gründer G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr. Opin. Investig. Drugs 11(7), 823-832 (2010).
80. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv. Ther. 30(2), 114-126 (2013).
81. Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv. Ther. 30(2), 102-113 (2013).
82. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int. J. Neuropsychopharmacol. 16(6), 1433-1442 (2013).
83. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl.) 216(4), 451-473 (2011).
84. Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs 8(7), 539-554 (2007).
85. Spiros A, Carr R, Geerts H. Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatr. Dis. Treat. 6, 589-603 (2010).
86. Strange PG. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 29(6), 314-321 (2008).
87. Stahl SM. Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Specr. 13(4), 279-282 (2008).
88. Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 6(1), 78-85 (2009).
89. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63(1), 182-217 (2011).
90. Leopoldo M, Berardi F, Colabufo NA et al. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl] arylcarboxamides as potent and selective dopamine D3 receptor ligands. J. Med. Chem. 45(26), 5727-5735 (2002).
91. Newman AH, Cao J, Bennett CJ et al. N-(4-[4-(2,3-dichlorophenyl) piperazin-1-yl] butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D3 receptor antagonists. Bioorg. Med. Chem. Lett. 13(13), 2179-2183 (2003).
92. Newman AH, Grundt P, Cyriac G et al. N-(4-(4-(2,3-dichloro-or 2-methoxyphenyl) piperazin-1-yl)butyl) heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J. Med. Chem. 52(8), 2559-2570 (2009).
93. Banala AK, Levy BA, Khatri SS et al. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl) arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J. Med. Chem. 54(10), 3581-3594 (2011).
94. Chen J, Ding K, Levant B, Wang S. Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility. Bioorg. Med. Chem. Lett. 16(2), 443-446 (2006).
95. Austin NE, Avenell KY, Boyfield I et al. Novel 1,2,3,4- tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor. Bioorg. Med. Chem. Lett. 9(2), 179-184 (1999).
96. Stemp G, Ashmeade T, Branch CL et al. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl) ethyl]cyclohexyl]-4- quinolinecarboxamide (SB-277011): a potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. J. Med. Chem. 43(9), 1878-1885 (2000).
97. Jahnke U. Experimental pharmacotherapeutics for schizophrenia and addiction. IDrugs 11(1), 7-9 (2008).
98. Agai-Csongor E, Nógrádi K, Galambos J et al. Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile. Bioorg. Med. Chem. Lett. 17(19), 5340-5344 (2007).
99. Agai-CsongorE, Domány G, Nógrádi K et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg. Med. Chem. Lett. 22(10), 3437-3440 (2012).
100. Butini S, Gemma S, Campiani G et al. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J. Med. Chem. 52(1), 151-169 (2009).
101. Allen AJ, Yost JM, Setola V et al. Discovery of ?-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl Acad. Sci. USA 108(45), 18488-18493 (2011).
102. Zajdel P, Marciniec K, Ma?lankiewicz A et al. Quinoline-and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5- HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation. Bioorg. Med. Chem. 20(4), 1545-1556 (2012).
103. Zajdel P, Marciniec K, Ma?lankiewicz A et al. Antidepressant and antipsychotic activity of new quinoline-and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. Eur. J. Med. Chem. 60, 42-50 (2013).
104. ZajdelP, Marciniec K, Ma?lankiewicz A et al. Arene-and quinoline-sulfonamides as novel 5-HT7 receptor ligands. Bioorg. Med. Chem. 19(22), 6750-6759 (2011).
105. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13(7), 272-276 (1990).
106. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20(3), 201-225 (1999).